| NCT ID | NCT04237675 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Athens |
| Condition | Multiple Sclerosis Relapse |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2019-12-20 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2019-12-20 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to record any relapses during one year postoperatively in patients and parturients diagnosed with MS who received general or regional anesthesia
Eligibility Criteria
Inclusion Criteria: diagnosed MS - Exclusion Criteria: refuse to participate \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04237675 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Multiple Sclerosis Relapse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04237675 currently recruiting?
Yes, NCT04237675 is actively recruiting participants. Contact the research team at c_staikou@yahoo.gr for enrollment information.
Where is the NCT04237675 trial being conducted?
This trial is being conducted at Athens, Greece, Athens, Greece.
Who is sponsoring the NCT04237675 clinical trial?
NCT04237675 is sponsored by University of Athens. The trial plans to enroll 300 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.